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Abstract The entire drug safety enterprise has a need to
search, retrieve, evaluate, and synthesize scientific evidence
more efficiently. This discovery and synthesis process would be
greatly accelerated through access to a common framework
that brings all relevant information sources together within a
standardized structure. This presents an opportunity to establish
an open-source community effort to develop a global knowl-
edge base, one that brings together and standardizes all avail-
able information for all drugs and all health outcomes of interest
(HOIs) from all electronic sources pertinent to drug safety. To
make this vision a reality, we have established a workgroup
within the Observational Health Data Sciences and Informatics
(OHDSI, http://ohdsi.org) collaborative. The workgroup’s
mission is to develop an open-source standardized knowledge
base for the effects of medical products and an efficient pro-
cedure for maintaining and expanding it. The knowledge base
will make it simpler for practitioners to access, retrieve, and
synthesize evidence so that they can reach a rigorous and
accurate assessment of causal relationships between a given
drug and HOI. Development of the knowledge base will pro-
ceed with the measureable goal of supporting an efficient and
thorough evidence-based assessment of the effects of 1,000
active ingredients across 100 HOIs. This non-trivial task will
result in a high-quality and generally applicable drug safety
knowledge base. It will also yield a reference standard of drug–
HOI pairs that will enable more advanced methodological
research that empirically evaluates the performance of drug
safety analysis methods.
Key Points
The individuals who possess the expertise to synthesize
evidence on a medication’s safety are hindered by
numerous disconnected ‘‘islands of information’’
A workgroup within the Observational Health Data
Sciences and Informatics (OHDSI, http://ohdsi.org)
collaborative is addressing this issue by establishing
an open-source community effort to develop a global
knowledge base that brings together and standardizes
all available information for all drugs and all health
outcomes of interest from all electronic sources
pertinent to drug safety
Striving toward the goal of a generally useful
knowledge base, though ambitious, is necessary for
advancing the science of drug safety because it will
make it simpler for practitioners to access, retrieve,
and synthesize evidence so that they can reach a
rigorous and accurate assessment of causal
relationships between a given drug and the health
outcome of interest
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1 Introduction
‘‘The investigator is staggered by the findings and
conclusions of thousands of other workers—conclu-
sions which he cannot find time to grasp, much less to
remember, as they appear.’’—Bush 1945 [1]
When Dr. Vannevar Bush penned this lament 7 decades
ago, the then Director of the United States Office of Sci-
entific Research and Development was calling post-World
War II scientists to conduct research that would yield a
revolutionary approach to representing and retrieving
information. At the time, distributed document collections
and taxonomic indexing schemes were hindering the ability
of researchers to identify important connections that could
yield new scientific insights. The Internet, electronic doc-
ument collections, hypertext, advanced information retrie-
val systems, and digital social networks are some of the
many advances since Dr. Bush first articulated his vision.
Unfortunately, his lament still resonates with the contem-
porary drug safety practitioner. Today, an overwhelming
amount of drug safety-relevant information is being gen-
erated and stored in a wide array of disparate information
sources using differing terminologies at a faster pace than
ever before. Product manufacturers, regulatory agencies,
and prescribers have an obligation to the public to correctly
interpret and properly act on this information in a timely
manner. However, the individuals who possess the exper-
tise to synthesize evidence on a medication’s safety are
hindered by numerous disconnected ‘‘islands of
information.’’
Like a photo mosaic, a clear and understandable image
of a potential drug safety issue can emerge when the rel-
evant sources of evidence are brought together. The written
protocol for a pre-marketing drug trial can help determine
if an adverse event mentioned in a spontaneous report is
causally related to the drug exposure or the condition being
treated. A well-designed observational study using elec-
tronic health records data can suggest what categories of
patients would be most at risk for developing an adverse
drug reaction listed in product labeling. A published case
report can add credence to a potential drug–adverse event
association identified by mining spontaneous reporting data
or longitudinal observational health databases. A system-
atic review of clinical trials testing a drug’s efficacy for an
off-label indication can provide data on adverse events that
can occur in populations not mentioned in drug product
labeling. A knowledge base (KB) of drug pharmacological
properties and molecular targets can yield information
useful for inferring the biological plausibility of a sus-
pected drug-related adverse event.
Unfortunately, the information from these and many
other potentially useful sources is stored in different sys-
tems with distinct information formats, employing non-
interoperable terminology schemes, and requiring unique
skills to navigate and explore (Table 1). This situation
makes it extremely time consuming and resource intensive
to retrieve the necessary information when conducting a
comprehensive assessment of a potential safety signal. The
investigation of drug safety concerns tends to be manual,
highly iterative, with a steep learning curve, and perpetu-
ally at risk for errors of omission due to the complexities
involved in searching across multiple domains for related
information.
The entire drug safety enterprise has a need to search,
retrieve, evaluate, and synthesize scientific evidence more
efficiently. This presents a tremendous opportunity to
establish an open-source community effort to develop a
global KB, one that brings together and standardizes all
available information for all drugs and all health outcomes
of interest (HOIs) from all electronic sources pertinent to
drug safety. The community needs to go beyond simply
enabling cross-resource queries to establish an empirical
evidence base about the reliability of information sources
used in the drug safety assessment process.
The quote by Dr. Vannevar Bush at the beginning of this
paper is taken from a paper in which he invited post-war
scientists to use emerging technologies such as photocells,
cathode ray tubes, and ‘‘arithmetical machines’’ (very early
computers) to make the ever growing scientific record
much more natural to synthesize. Were he alive today, he
might suggest relatively recent technologies such as bio-
medical ontologies [2], Semantic Web Linked Data [3],
natural language processing, and machine learning.
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Biomedical ontologies and Semantic Web Linked Data
would be recommended for their potential to enable all
sources to be integrated in a way that allows for both
summative queries (e.g., ‘‘How many data sources suggest
that drug X is associated with HOI Y?’’) and the ability to
‘‘drill down’’ into specific data sources (e.g., ‘‘When did
source A first suggest that drug X is associated with HOI
Y?’’); natural language processing would be recommended
for its potential to enable the addition of knowledge men-
tioned within the text documents (e.g., adverse drug reac-
tions recorded in tables and sections of drug product
labeling); and machine learning would be recommended
for its potential to automate much of the process for
identifying positive and negative drug–HOI associations.
Moreover, innovative sources of drug safety evidence, such
as inferences derived from predictive methods emerging
from the nascent field of network medicine [4] and weblogs
[5], should be considered as potentially valuable additional
forms of evidence.
To make this vision a reality, we have established a
workgroup within the Observational Health Data Sciences
and Informatics (OHDSI, http://ohdsi.org) collaborative.
The workgroup’s mission is to establish an open-source
standardized KB for the effects of medical products and an
efficient semi-automated procedure for maintaining and
expanding it.
2 A Focal Point for the Integration of Information
Sources Relevant to Drug Safety
We believe that development of the proposed KB should
proceed with the measureable goal of supporting an effi-
cient and thorough evidence-based assessment of the
effects of 1,000 active ingredients across 100 HOIs. This
non-trivial task will result in a high-quality and generally
applicable drug safety KB, providing a focal point to guide
design decisions. These include what information sources
to include, what terminologies to employ, how to handle
data that comes with uncertainty (e.g., associations mined
from spontaneous reports, risks identified in pharmacoep-
idemiological studies, or the output of processing the sci-
entific literature using natural language processing
algorithms), and how to accommodate conflicting evi-
dence. The large-scale evidence assessment task will also
be a major contribution to the global drug safety research
community because it will yield a reference standard of
drug–HOI pairs that will enable more advanced methodo-
logical research that empirically evaluates the performance
of drug safety analysis methods.
The target of 1,000 drugs is motivated by the fact that
this number represents a significant proportion of the drugs
used in practice. At the time of this writing, we estimate
that it would represent 64 % of the 1,565 unique active
ingredients listed in the drugs@FDA database as currently
marketed for prescription or over-the-counter use in the
USA (though the choice of drugs will not be limited to a
single country’s market). The choice of 100 HOIs is
motivated by the fact that the number is sufficiently greater
than previous efforts so as to spur innovative approaches to
making the drug–HOI assessments more efficient. The
specific list of drugs and HOIs will include those already
examined in previous references standards and those con-
sidered to be high priority by our pharmacovigilance col-
laborators. We will further extend the drug list to ensure a
representative sample, taking into account such attributes
as marketing duration, pharmacological class, and preva-
lence of exposure. Similarly, we will choose additional
HOIs so as to ensure an accurate representation of severity,
system/organ class, and likelihood of mention in various
sources.
2.1 The Broad Utility of a Drug Safety KB
Considering a given HOI, one of a drug safety practi-
tioner’s main tasks is to search for all relevant evidence for
a positive or negative association between any drug and the
HOI and synthesize that evidence to make a final judgment
on the veracity of the association. Practitioners routinely
need to review disparate information from scientific liter-
ature, product labeling, spontaneous adverse reports,
observational health data, and other sources. This discov-
ery and synthesis process would be greatly accelerated
through access to a common framework that brings all of
these information sources together within a standardized
structure.
It is also quite possible that the KB will have value
beyond drug safety; product manufacturers may use the
information to assess areas of unmet medical need or
identify targets for drug re-purposing, providers may use
this information to support clinical decisions, and patients
may benefit from access to a standard, easy-to-use interface
that provides consistent information about their treatments
and their potential effects. Moreover the OHDSI KB will
directly impact methodological research and empirical
evaluation of drug safety methods by enabling the devel-
opment of a globally acceptable drug–HOI reference set.
2.2 The Need for a Globally Acceptable Drug–HOI
Reference Standard
Over the past decade, a number of experiments have been
performed to estimate the ability of drug safety analysis
methods to discriminate between drugs causally related
with specific HOIs (drug–HOI ‘‘positive controls’’) and
drugs that have no causal relation (drug–HOI ‘‘negative
560 R. D. Boyce et al.
controls’’), measure the expected time to detection, and
quantify the magnitude of error that should be anticipated
from any effect estimate [6–20]. The primary means for
conducting these methodological experiments is to perform
a retrospective evaluation that compares the results from
the drug safety analysis process with some pre-defined
reference standard. Ideally, a reference standard would
represent a large collection of drug–HOI combinations, be
based on complete and certain information about the
strength of association, and provide the provenance (e.g.,
source and date of creation) of evidence items used to
develop the standard. In practice, the task of establishing a
reference standard involves resource-intensive information
gathering and decision-making under uncertainty.
To illustrate the varying approaches to creating a ref-
erence set, Table 2 highlights the evidence sources and
sampling frame from five recent methodological experi-
ments where drug–HOI reference sets were developed.
The reference standards developed by Hochberg et al. [19]
and Alvarez et al. [17] were initially used to support
evaluation of spontaneous adverse event reporting analy-
ses, whereas the Observational Medical Outcomes Part-
nership (OMOP) [8, 21] and Exploring and Understanding
Adverse Drug Reactions by Integrative Mining of Clinical
Records and Biomedical Knowledge (EU-ADR) [22]
reference sets were designed to facilitate research in
observational health databases. What is most striking in
this summary is that the different approaches employed
to select and evaluate drug–HOI cases resulted in
heterogeneous reference standards with different degrees
of confidence in the final output.
A shared experience across these efforts was that care-
fully and thoughtfully specifying the criteria for estab-
lishing a positive or negative drug–HOI association is a
tremendous amount of work. There was a sense of dissat-
isfaction that each reference set was neither large enough to
allow for the breadth of analyses desired, nor sufficiently
impervious to post hoc criticism. Each reference set was an
important contribution to their respective efforts, while at
the same time insufficient to meet the broad needs of the
drug safety research community. We believe that the
thorough evidence-based assessment of the effects of 1,000
active ingredients across 100 HOIs while developing the
OHDSI KB will lead to a more globally useful reference
standard because the task will bring together medication
safety practitioners and domain experts with informatics
experts who possess the technical skills necessary to
implement a standardized, reproducible process for struc-
tured evidence synthesis.
3 Early Progress on the KB
3.1 The Information Sources
Figure 1 outlines the information sources proposed for the
OHDSI KB and the necessary mappings to standardize the
content across the sources. As a starting point, we have
Table 2 Reference sets established to support methodological research in drug safety
Positive
controls
Negative
controls
Labeling Literature Spontaneous
data
Observational
data
Mechanism
of action
Sampling frame
Alvarez
et al.
[17]
532 x 267 centrally authorized drugs in
EU with at least 1 year of safety
information submitted by
manufacturer, time-stamped with
when the safety issue was first
brought up for discussion within
the EMA Signal Management
Team
Hochberg
et al.
[19]
6,207 x x 35 drugs approved in 2000, 2002,
and 2004
OMOP v1
[8]
9 44 x x x Chose ten drug-outcome positive
controls, looked for negative
controls within matrix of ten
drugs and ten outcomes
OMOP v2
[21]
165 234 x x Four outcomes, goal to find all
positives/negatives meeting
criteria
EU-ADR
[22]
44 50 x x x x Ten outcomes, goal to find five
positives/five negatives
EMA European Medicines Agency, EU European Union, OMOP Observational Medical Outcomes Partnership, EU-ADR Exploring and
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chosen RxNorm [23] as the standard terminology for drugs,
and Systematized Nomenclature of Medicine-Clinical
Terms (SNOMED-CT) [24] as the standard terminology for
conditions. This decision is motivated by prior work by
OHDSI collaborators who lead the development of the
OMOP common data model [25] and standard vocabulary
[26]. The vocabulary provides mappings from RxNorm to
various drug classification systems such as the Enhanced
Therapeutic Classification maintained by First Databank
(FDBTM), the World Health Organization (WHO) Ana-
tomical Therapeutic Chemical Classification System (ATC),
and the Veteran’s Administration National Drug File-Ref-
erence Terminology (NDF-RT) [26]. That vocabulary also
contains mappings from various sources of diagnosis ter-
minologies, such as the International Classification of Dis-
eases, Revision 9 (ICD-9) and Revision 10 (ICD-10), into
SNOMED-CT and from SNOMED-CT conditions to Med-
ical Dictionary for Regulatory Activities (MedDRA). We
will build on previous work to extend the vocabulary to link
RxNorm to DrugBank [27]. This will allow for ‘‘snowball’’
integration of mappings from RxNorm to chemicals and
protein targets (ChEMBL and PubChem), genes (UniProt),
gene–disease associations in other National Center for
Biotechnology Information databases, and back to
SNOMED-CT via Disease Ontology [28].
Other sources shown in Fig. 1 include spontaneous
adverse event reporting data from the US Food and Drug
Administration (FDA) Adverse Event Reporting System
(FAERS) and WHO VigiBase, which allows for dispro-
portionality analysis. Additional information on adverse
events will come from the ClinicalTrials.gov clinical trials
registry [29], which now links adverse events reported
during clinical trials to important intervention and study
design information. A subset of PubMed will be filtered as
described above, and the KB will provide links from
Medical Subject Headings (MeSH) concepts to RxNorm
drugs and SNOMED-CT conditions. US Structured Prod-
uct Labeling (SPL) contains tagged entities for drug active
ingredients that the KB will link to RxNorm drugs. Also,
we will use a text mining tool called SPLICER to extract
adverse event information present in the boxed warnings,
warning/precaution, and adverse reaction sections of SPLs,
and link the extracted information to RxNorm drugs and
SNOMED-CT conditions [30, 31]. The KB will also
include drug–HOI association data derived from observa-
tional healthcare datasets, using methods developed during
the OMOP and EU-ADR efforts [6–16].
3.2 Iterative Development of the Reference Standard,
Incremental Extensions to the KB
To be successful, the KB has to make it simpler for prac-
titioners to access, retrieve, and synthesize evidence so that
they can reach a rigorous and accurate assessment of causal
relationships between a given drug and HOI. Given a
potential causal relationship, there might be a need to
assess causality at the individual case level or at the
‘‘global’’ level that considers the overall body evidence. In
individual cases, a number of structured decision processes
have been proposed since the 1970s [32], ranging from
simple psychometrically weighted questionnaires [33–36]
to probabilistic algorithms that calculate the probability in
favor of a drug–HOI association on the basis of epidemi-
ological and patient case information [37, 38]. Our task is
not to judge between these processes, but to help practi-
tioners more efficiently gather together information that
would help them use the process they deem most appro-
priate for a given task (e.g., prior reports and the preva-
lence of events in exposed and non-exposed patients).
Practitioners assessing the total body of evidence for a
drug–HOI association would benefit from the KB’s com-
prehensive inclusion of evidence sources and its ability to
query across all of the sources, using a small set of stan-
dardized vocabularies.
Figure 2 shows the iterative process we plan to use to
accomplish these goals. The OHDSI team will select an initial
set of data sources and integrate them into a common format.
All content in this initial version of the KB will be time-
stamped for when it was generated (e.g., the date when rele-
vant case reports, observational studies and randomized
controlled trials were published in scientific journals, when
disproportionality analysis met signaling thresholds in spon-
taneous reporting systems, and when adverse events were
added to product labeling). It is also important to note that the
KB will include evidence items that report no finding of a
causal association between a drug and HOI so that experts will
be able to gather information from all relevant sources.
An important goal of this project is to develop a more
automated process for establishing positive and negative
control drug–HOI associations. Toward that end, a panel of
drug safety experts will use the first version of the KB to
review existing reference sets (Table 2) and establish an
initial ‘‘silver’’ standard of drug–HOI associations that the
panel finds credible with a high level of inter-rater agree-
ment. This ‘‘silver’’ standard will serve as the basis for
training a classification model, which will take as inputs
features (‘‘covariates’’) derived from the KB and output
predicted positive and negative drug–HOI associations. We
will also see if the model is able to predict any associations
identified by regulatory bodies or published case reports
that the panel reviews after initial construction of the KB.
Iterative versions of the model will be developed as the
expert panel proceeds to evaluate drug–HOI combinations
from the 1,000 9 100 matrix.
The process described above, and shown in Fig. 2, will
also help identify changes that will enhance the usability of
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the KB for future users. At the same time, an error analysis
of the prediction algorithm will help us to identify neces-
sary modifications to the information sources or integration
methods that might improve prediction accuracy. This
entire procedure will be repeated, iteratively expanding the
‘‘silver’’ standard and improving the KB, until the expert
panel accomplishes the evidence assessment goal. The
result will be a reference standard covering the
1,000 9 100 matrix and a predictive model (or family of
models) that accurately classifies whether a given drug is
related to an HOI, on the basis of the available evidence
from all sources (Fig. 3). High-performance models might
ultimately provide a probabilistic evidence-based assess-
ment for all drug–HOI pairs.
As the KB matures, we will explore the value of
including innovative sources of drug safety evidence, such
as inferences derived from biomedical ontologies and
predictive methods emerging from the nascent field of
network medicine [4]. A number of new methods are worth
considering, including Duke et al.’s [39] template-based
approach to inferring drug-interaction predictions using
metabolic pathways extracted from the scientific literature,
models that infer adverse events from graphical models of
drug and conditions [40–42], and methods that use inno-
vative approaches to overcome known limitations of drug
safety sources such as spontaneous adverse event reports
[18] and electronic healthcare databases [43]. As each
information source is brought into the KB, we will
empirically assess its added value in classifying drug–
outcome pairs. By tying the quality and coverage of the KB
to explicit performance characteristics, we will know if an
addition to the KB moves us toward or away from a more
systematically informed scientific process.
4 A Hypothetical Example of Using the OHDSI KB
Here, we provide a hypothetical example of how the KB
might be used to reconcile of disparate sources of evidence
relevant to assessing a drug–HOI association. Imagine that
Fig. 1 Information sources proposed for the initial version of the OHDSI knowledge base. ATC Anatomical Therapeutic Chemical Classification
System, EHR electronic health record, FAERS Federal Drug Administration Adverse Event Reporting System, FDBTM First DataBank, GAD
Genetic Association Database, GPI Generic Product Identifier, GWAS Genome-wide association study, HOI health outcome of interest, ICD-10
International Classification of Diseases, Tenth Revision, ICD-9-CM International Classification of Diseases, Ninth Revision, Clinical
Modification, MeSH Medical Subject Headings, NDC National Drug Code Directory, NDF-RT National Drug File-Reference Terminology,
OHDSI Observational Health Data Sciences and Informatics, OMIM Online Mendelian Inheritance in Man, SmPC EU Summary of Product
Characteristics, SNOMED Systematized Nomenclature of Medicine, SPL Structured Produce Labeling
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an expert is investigating the possible association of some
active ingredient (Drug X) with kidney injury. The expert
would query the KB using the RxNorm identifier for Drug
X and the SNOMED term Renal failure syndrome (disor-
der). Results from this hypothetical query are shown in
Table 3. The first columns show some basic information,
including that there is no known contraindication between
the drug and HOI. The remaining columns show the
sources of evidence available in the KB with additional
information including:
• whether the HOI is mentioned as an adverse drug
reaction in product labeling and when it first appeared
in each source,
• the number of studies indexed in the scientific litera-
tures in which drug and HOI terms co-occur,
• whether pharmacovigilance signals have been identified
from spontaneous reporting, which datasets, and when,
• whether pharmacovigilance signals have been identified
in electronic health records data, which datasets, and when
After reviewing this initial summary of the evidence
available in the KB, the expert can ‘‘drill down’’ to
examine relevant details. Underlined text in Table 3
indicates hyperlinks that will take the expert directly to
more detailed information. Figure 3 shows that the specific
information that the KB will provide is driven by expert
users as we develop the KB.
Fig. 2 A systems view of
OHDSI knowledge base
development. HOI health
outcome of interest, OHDSI
Observational Health Data
Sciences and Informatics
Table 3 Hypothetical output of the knowledge base when queried for evidence of an association between drug X and renal failure. Bold text
indicates hypothetical hyperlinks that will take the expert directly to more detailed information
Drug ATC HOI Contra-
indicated
US SPL EU SmPC Scientific
literature
FDA
FAERS
VigiBase EHR/Claims
data
X Beta
blocker
Renal failure
syndrome
(disorder)
False 1 Renal
failure
(1998)
1 Renal failure
acute (2001)
13 publications
(1998–)
Out of which:
3 case report
(2001–)
2 RCTs (1998–)
8 observational
studies (2003–)
0 systematic
reviews
110
reports
PRR:
4.5
Renal
failure
(April 1
2014)
148
reports
PRR: 3.3
Renal
failure
(April 1
2014)
Associations:
Medicare
OR: 3.3
Medicaid
OR: 2.2
ATC Anatomical Therapeutic Chemical Classification System, EHR electronic health record, EU European Union, FAERS FDA Adverse Event
Reporting System, FDA US Food and Drug Administration, HOI health outcome of interest, OR odds ratio, PRR proportional reporting ratio,
RCT randomized controlled trial, SmPC Summary of Product Characteristics, SPL Structured Product Labeling
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5 Summary and Conclusions
We believe that striving toward the goal of a generally
useful KB, though ambitious, is necessary for advancing
the science of drug safety. Individually, each data source is
insufficient to provide the evidence required for a reliable
inference in the general case and a reference set in our
specific case. Spontaneous adverse event reporting data
remains a foundational component of drug safety, but well-
acknowledged limitations of underreporting and lack of an
available denominator make analysis of these data subject
to various sources of bias [2, 3, 26, 29, 44, 45]. Product
labeling serves as a primary source of information col-
lected during the clinical development program, but pri-
marily originates from clinical trials that are often
underpowered for detecting rare adverse events, have
insufficient follow-up for long-term adverse events, and
comprise patient populations who may not be representa-
tive of the patients exposed to the drug in the real world.
The level of confidence that adverse event information is
credible versus ‘‘overwarning’’ can vary on the basis of
whether it is mentioned in the boxed warning, precautions,
or adverse reactions sections. Moreover, it is often the case
that only limited supporting data are available to quantify
the risk of a mentioned adverse event, and products can
have multiple labels with inconsistent safety information
[30, 46]. Observational databases often offer the largest
source for patient-level data with real-world experience,
but epidemiological studies are often challenged by con-
founding and other sources of bias that threaten the validity
of results. While each contributing data source has sub-
stantial limitations, we believe that these can be substan-
tially mitigated by the KB development approach that we
propose.
In addition to generating the KB, we also plan to work
toward an efficient automated process for regular mainte-
nance and revision. Currency of information is of consider-
able interest in drug safety, as product manufacturers and
regulatory agencies strive to identify drug-related adverse
events as soon as possible during the lifecycle of the product,
Fig. 3 Expert users will drive both the content of the knowledge base and provide feedback that will help improve the drug–HOI prediction
algorithm. In this hypothetical example, the experts are able to ‘‘drill down’’ to review important information on various evidence items present
in the KB that support an association between drug X and renal failure. ATC Anatomical Therapeutic Chemical Classification System, EHR
electronic health record, HOI health outcome of interest, KB knowledge base, OHDSI Observational Health Data Sciences and Informatics
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and providers and patients expect that their medical decision-
making can be informed by the most reliable and timely
evidence available. The systematic upkeep of the KB will not
only preserve relative consistency between the original
sources and the composite summary as knowledge evolves
over time, but might also facilitate more efficient evidence
dissemination across all interested stakeholders.
To be sustainable, the KB requires an open-source,
community-led effort that complements the other existing
business models to offer the entire community a more
complete solution to the problem. By bringing together
pharmacovigilance and informatics experts into an open
collaboration, we expect feedback from stakeholders that
will help identify missing information, sources that should
be added to the KB, and corrections or modifications to the
sources represented in the KB. Persons interested in
become collaborators can contact us directly or through the
OHDSI project management site (http://goo.gl/TRSUoH)
or the OHDSI code development sites (https://github.com/
OHDSI/KnowledgeBase).
In conclusion, we are excited to help jumpstart this
community effort, as we fully expect a drug safety KB will
become an invaluable tool for methodological research and
pharmacovigilance practice alike.
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